Asthma Pipeline Pressure For AstraZeneca As STRATOS 1 Fails
The failure of AstraZeneca's novel asthma therapy in its first pivotal trial is of little surprise but increases the pressure on its other late-stage asthma product in this key therapy area for the company.
